Certoparin

DB09261ApprovedSmall molecule

Certoparin is a low molecular weight heparin (LMWH) used to prevent blood clots, specifically deep vein thrombosis. Certoparin is part of the heparins of low molecular weight that presents high activity against the coagulation factor Xa.

Mechanism
Curator reviewed
Primary indication
Used in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.Curator reviewed · 6 structured indications

Resolves to

Compound
UNIIV72OT3K19I
Clinical / RWD
RxNorm152610
Targets
P00742F10

What you can answer from here — as of July 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
341Drug interactionsStructured to mechanism, not free text
Sign in
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
6Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
21ContraindicationsEach with its own population and attribute set
Sign in
7Marketed productsAcross every region we cover
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Certoparin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In